6-Month Data From the Surmodics Avess(TM) AV Fistula DCB First-in-Human Study Presented at VIVA 2020; Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months
Nov 09, 2020 - Business Wire
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from the AVESS first-in-human (FIH) study of the company's Avess(TM) AV Fistula drug-coated balloon (DCB) was shared during a morning session at the Vascular Interventional Advances (VIVA) 2020 virtual conference.
The AVESS study is a prospective, multi-center, single-arm study to assess the safety and performance of the Ave...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
